CMMB · Chemomab Therapeutics Ltd.

Chemomab Therapeutics reported its first quarter 2026 financial results, highlighting a reduced net loss of $1.8 million compared to $3.3 million in the same period last year. The improvement was primarily driven by a significant decrease in research and development expenses, which fell to $0.9 million from $2.5 million, reflecting the winding down of activities related to the Phase 2 SPRING trial. General and administrative expenses remained relatively stable at $0.9 million. The company ended the quarter with $8.0 million in cash, cash equivalents, and short-term bank deposits, down from $10.4 million at year-end 2025, providing a runway through the first quarter of 2027. Operationally, Chemomab presented new clinical and translational data at major medical meetings, including Digestive Disease Week and the upcoming EASL Congress, further validating the disease-modifying potential of nebokitug in primary sclerosing cholangitis (PSC) and suggesting additional benefits in PSC patients with co-existing inflammatory bowel disease (IBD). The company continues to advance multiple partnering options for nebokitug. Management expressed confidence in nebokitug's potential to become the first FDA-approved disease-modifying treatment for PSC, with differentiated benefits for the large PSC-IBD patient population.